Drug Trial Radar · NCT07941622
Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Dec 28, 2026
Primary completion
Apr 27, 2028
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 days, up to 45 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers. Study details include: * The study duration per participant will be approximately 18 months. * The study vaccines administration: * Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA. * Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.
Conditions
- Haemophilus Influenzae Type b Immunisation
- Hepatitis B Immunisation
- Polio Immunization
- Pertussis Immunisation
- Diphtheria Immunisation
- Tetanus Immunisation
- Healthy Volunteers
Interventions
DTaP-IPV-HB-PRP~T combined vaccineBiological
Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection
DTaP-IPV//PRP~T combined vaccineBiological
Pharmaceutical form:Freeze-dried PRP\~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection
monovalent Hep B vaccineBiological
Pharmaceutical form: Depending on the brand procured Route of administration:IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):Time frame: Day181
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.